We develop microbially-expressed proteins for therapeutic use through aspectic processing. One of the products we are currently engaged in is recombinant streptokinase injection, a thrombolytic drug used for treating acute myocardial infarction (AMI).
AMI, commonly known as “heart attack” is a life-threatening cardiovascular condition caused by the abrupt blockage of blood flow to the heart resulting in tissue damage. AMI affects a high proportion of population in India & major parts of the world. Streptokinase is used as a life-saving medication and often the first line of treatment for this condition.
On the innovation front, we are currently involved in developing proprietary drug delivery technologies for small and large molecules (<20KDa), that would serve as a platform technology for overcoming the limitations of current liposomal and polymer-encapsulation technologies such as inefficient bioavailability, early degradation/short half-life, uncontrolled release patterns, burst-release phenomena and non-targeted delivery.